(INNS)
TECAGINLIMAB(INND)
TEKAGINLIMAB(INNC)
IMMUNOGLOBULIN G1-KAPPA, ANTI-[HOMO SAPIENS CD40 (TUMOR NECROSIS FACTOR RECEPTOR SUPERFAMILY MEMBER 5, TNFRSF5, P50)] AND ANTI-[HOMO SAPIENS TNFRSF9 (TUMOR NECROSIS FACTOR RECEPTOR (TNFR) SUPERFAMILY MEMBER 9, 4-1BB, T CELL ANTIGEN ILA, CD137)], HUMANIZED MONOCLONAL ANTIBODY, BISPECIFIC; GAMMA1 HEAVY CHAIN HUMANIZED ANTI-CD40 (1-451) [VH ANTI-CD40 (HOMO SAPIENS IGHV1-46*01 (85.7%) - (IGHD)-IGHJ4*01 (92.9%), CDR-IMGT [8.8.15] (26- 33.51-58.97-111)) (1-122) -HOMO SAPIENS IGHG1*03, G1M3, NG1M1, G1V41 CH2 F1.3, E1.2 (CH1 R120 (219) (123-220), HINGE 1-15 (221-235), CH2 L1.3>F (239), L1.2>E (240), D27>A (270) (236-345), CH3 E12 (361), M14 (363), F85.1>L (410) (346-450),...; PROPOSED INN: LIST 125, RECOMMENDED INN: LIST 87(WHO)
TECAGINLIMABUM(INN)